The Egyptian Hypertension Society

EGYPTIAN HYPERTENSION GUIDELINES

2020
From the President of EHS

The main objectives of this document are to provide the practitioners in Egypt with an up-to-date information regarding the management of hypertension in a poor resources’ setting and help answering practical questions seen in daily practice. The development of guidelines took into consideration the low socioeconomic status of the majority of the Egyptian patients, the defective health care system in our country- majority of public pay out of their own pocket to cover the health costs, in addition to the limited medical education in the field. The target physician population for these guidelines is the general practitioners, family doctors, internists and those who are taking care of hypertensive patients.

Principal Editor
M. Mohsen Ibrahim, MD
President of the Egyptian Hypertension Society
Cairo 2020
Working Group Members

Principal Editor:
M. Mohsen Ibrahim 
Cairo University

Members (Alphabetically):
Ahmed Abdel latief Ramadan 
Al-Azhar University
Ahmed El-Hawary 
Suez Canal University
Amir Abdel Wahab 
Cairo University
Amr Hassan 
Cairo University
Aziz Madkour 
Al-Azhar University
Azza El-Eraky 
Suez Canal University
Azza Farrag 
Cairo University
Ezz El-Sawy 
Al-Azhar University
Fathy Maklady 
Suez Canal University
Ghada Sayed 
Cairo University
Hany Ragy 
National Heart Institute
Heba Gabr 
Ministry of Health
Hossam Kandil 
Cairo University
Hussien Heshmat 
Cairo University
Hussien Rizk 
Cairo University
Karim Said 
Cairo University
Magdy Abdel Hamid 
Cairo University
Maher Fouad Ramzy 
Cairo University
Mahmoud Hassanien 
Alexandria University
Mohamed Abdel Ghany 
Cairo University
Mohamed Oraby 
Suez Canal University
Nasser Taha 
Menia University
Omar Awwad 
Ain Shams University
Omar El-Khashab 
Cairo University
Sameh Bakhoum 
Cairo University
Sameh Shahien 
Ain Shams University
Soliman Gharieb 
Cairo University
Wafaa El-Aroussy 
Cairo University
Wagdy Ayad 
Alexandria University
Yasser Boghdady 
Cairo University
DIAGNOSIS OF HYPERTENSION

1. Blood Pressure Measurement

- BP must be measured in a standardized fashion using a properly validated, well maintained and a recently calibrated device.
- Blood pressure is variable. The diagnosis of hypertension should be based on multiple BP measurements taken on several separate occasions.
- Cut-off point for defining hypertension during office measurement is 140/90 mmHg, while for average home readings and for daytime ambulatory blood pressure (ABP) is 135/85 mmHg.
- If all BP measurements are 140/90 mmHg or higher, to confirm the diagnosis of HTN, choose one or more of the following:
  1. Repeat office BP measurements 3-5 times over 2-3 months depending on BP level.
  2. Offer 24 hrs ABPM and the use of the average daytime BP.
  3. Home BP monitoring: take as many measurements as possible preferably more than 14 measurements over one week.
- End organ damage and CV event rates correlate more closely with ABPM than with clinic measurements.

Precautions to Obtain Correct BP Reading

1. Choose the correct cuff size.
2. Avoid placing the cuff over clothes.
3. Patient’s arm must be at heart level.
4. Patient should rest quietly for 3-5 minutes before measurement in a quiet room with comfortable temperature.
5. Patient should avoid talking during measurement.
6. No caffeine or cigarette smoking at least 1 hour before measurement.
7. Patient’s bladder should be evacuated.
8. Palpate radial pulse before auscultatory measurements (to avoid the auscultatory gap).
9. Do not deflate the cuff too quickly (2 mmHg/beat).
10. Do not re-inflate the cuff to repeat measurements before it is fully deflated.
11. Take more than one measurement.
12. If there is a difference of more than 10 mmHg between two measurements, take more measurements.
The diagnosis of hypertension should be based on at least 3 blood pressure measurements 30-60 seconds apart after resting for at least 5 minutes and on repeated office visits. If there is a difference of ≥ 10/5 mmHg between readings, take more measurements, take the lowest reading of the last 2 measurements. If the initial readings are high (>150/95 mmHg), have the patient rest for 5 minutes and repeat measurement.

Home BP measurement
- Self-measurement of BP at home is better than office measurements as it correlates with target organ damage (TOD), it detects white-coat and masked hypertension, it improves patient's adherence to therapy, and it is cheaper than frequent office visits.
- Normal home BP measurement should be less than 135/85 mmHg. Measure blood pressure twice daily for 7 days and take average of the last 6 days.

Ambulatory BP measurement (ABPM)
- ABP is the best method to diagnose hypertension but is not used for long-term follow-up. The major limitations are the cost and the inconvenience to the patient.
- Advantages of ABPM over office measurement:
  1. Better correlation to end-organ damage.
  2. Better prediction of cardiovascular events.
  4. No white coat effect.

Sequential Automated office BP (SABP)
- Use fully automated, validated, electronic sphygmomanometer.
- Device should take multiple readings without requiring activation of measurements by the patient or the health professional.
- Linked with TOD.
- More consistent from visit to visit.
- Eliminates office-induced HTN.

Cut-off points for Diagnosing HTN
1. Routine clinical practice: at office 140/90 mmHg.
2. Daytime: ABPM: ≥ 135/85 mmHg
3. Average home BP readings: ≥ 135/85 mmHg.
4. Average SABP readings: ≥ 135/85 mmHg.
Blood Pressure Variability

- Blood pressure is characterized by large spontaneous variations from time to time in a hypertensive patient during the day and between days, months and seasons. Therefore, the diagnosis of hypertension should be based on multiple blood pressure measurements, taken on separate occasions over a period of time.
- BP and heart rate should drop by 10-15% during sleep, a condition known as "dipping". Non dippers are at a higher risk of future cardiovascular events.

*Definition and classification of hypertension*

<table>
<thead>
<tr>
<th>Category</th>
<th>Systolic</th>
<th>Diastolic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>&lt; 140</td>
<td>And/or</td>
</tr>
<tr>
<td>Mild hypertension</td>
<td>140-159</td>
<td>And/or</td>
</tr>
<tr>
<td>Moderate hypertension</td>
<td>160-179</td>
<td>And/or</td>
</tr>
<tr>
<td>Severe hypertension</td>
<td>≥180</td>
<td>And/or</td>
</tr>
<tr>
<td>Isolated systolic hypertension</td>
<td>&gt;160</td>
<td>And</td>
</tr>
</tbody>
</table>

**Frequency of BP measurement**

*Interval between repeated measurements (office visits)*

- Mild HT (<160/100 mmHg): 2-3 months
- Moderate/severe (160/100-180/110 mmHg): 2-4 weeks
- TOD or high-risk patients: 2-4 weeks
- BP >180/110 mmHg: exclude panic attack or severe anxiety and repeat in 30 min

**White Coat Hypertension**

- In some patients, office blood pressure is persistently elevated while readings out of the office, ambulatory daytime or 24-hour ambulatory or home blood pressure, are within normal range. This condition is known as ‘white coat hypertension’ or isolated office hypertension.

**Masked Hypertension or Isolated Ambulatory Hypertension**

- Clinic BP is normal while out of office BP is high.
- Masked hypertension should be suspected if TOD progresses or does not resolve, despite BP control in the clinic.

**Pseudo Hypertension**

- Non compressibility artery syndrome causing falsely elevated blood pressure readings due to calcification of blood vessels which can not be compressed
Algorithm (1): Hypertension Diagnosis and Management

Initial visit
BP ≥ 140/90 mmHg

Initiate drug therapy in hypertensive emergencies, or if BP ≥ 180/110 mmHg after several readings*

Order Lab investigation

Second visit (2-3 weeks)

Risk stratification
- Risk factor
- TOD
- ACVD

BP ≥ 140-160/90-100 mmHg
No: RF-TOD-ACVD

Only LSM & FU

Confirm the diagnosis of hypertension

Repeated clinic BP (3-5 visits) ≥ 140/90 mmHg
HBPM ≥ 135/85 mmHg
Daytime ABPM ≥ 135/85 mmHg

RF-TOD-ACVD

Moderate Risk
Try LSM: 6 W

High Risk
Try LSM: 3 W

BP ≥ 140-90 mmHg
Drug Therapy

Very High Risk

* Excluding panic attack (severe anxiety)
ABPM: ambulatory blood pressure monitoring
ACVD: atherosclerotic cardiovascular disease
HBPM: home blood pressure monitoring
LSM: lifestyle modification, RF: risk factors, TOD: target organ damage, Lab investigation: urine, renal & lipid profile, blood sugar & ECG.
2. CLINICAL AND LABORATORY EVALUATION

Objectives

a. Identify high risk patients
   1. Detect other cardiovascular risk factors.
   2. Assess target organ damage.
   3. Diagnose associated cardiovascular or renal diseases.

b. Identify secondary causes of hypertension and comorbid conditions.

Laboratory Tests

- **Essential (for all patients):**

- **Recommended (if facilities are available):**
  - b. Uric acid.
  - c. Serum potassium.
  - d. Hemoglobin.
  - e. ECG.
  - f. Special investigations in resistant or suspected secondary forms of hypertension.
  - g. Optic fundus in patients with severe hypertension.

Assessment of Cardiovascular Risk Profile

The risk of cardiovascular disease in patients with hypertension is determined not only by the level of blood pressure but also by the presence or absence of target organ damage, other cardiovascular risk factors, associated clinical conditions and diabetes.

**Cardiovascular Risk Factors**

1. Diabetes mellitus: fasting plasma glucose >126 mg/dl, random plasma glucose >200 mg/dl or receiving treatment of diabetes or HbA1c >6.5 with symptoms of polyurea and polydypsia.
2. Males >55 or Females >65 years.
3. Total S-Cholesterol >240 mg/dl, HDL-C <40 mg/dl or LDL-C >160 mg/dl.
4. Cigarette smoking.
5. Obesity (BMI >30 kg/m²).
6. Serum creatinine >2 mg/dl.
7. Metabolic syndrome: combination of abdominal obesity (waist circumference >94 cm in men and >92 cm in women), impaired glucose tolerance (fasting blood sugar 110-126 mg/dl), increased plasma triglycerides (>200 mg/dl) and low HDL-C (<40 mg/dl).
8. Family history of atherosclerotic cardiovascular diseases in a first degree relative (parents, siblings or brothers) before the age of 40 years in males and 50 years in females.
Silent Target Organ Damage

- Left ventricular hypertrophy (LVH):
  a. ECG criteria (Sokolow- Lyon SV1+RV5 or V6 > 35 mm, tall R in AVL >11mm).
  b. Echo criteria (wall thickness ≥12 mm or LVMI in males ≥125 gm/m² or in females ≥110 gm/m²).
- Carotid bruits.
- Proteinuria*
- Increased serum creatinine >1.4 mg/dl in females and >1.5 mg/dl in males.
- Optic fundus changes: >grade I retinopathy.
* no proteinuria: < 30 mg/24 hrs
>300 mg macroalbuminuria
<300 mg microalbuminuria.

Cardiovascular Risk Categorization
Depending upon the global risk profiling, hypertensive patients can be categorized into four groups:

- **Low risk:**
  o No additional CV risk factors.
  o No TOD.
  o No associated atherosclerotic CV.
- **Moderate risk:**
  o 1-2 additional CV risk factors, no DM, no TOD and no atherosclerotic CVD.
- **High risk:**
  o >2 additional RFs, or TOD or DM or renal failure.
  o Very high level of a single risk factor.
- **Very high risk:**
  o Symptomatic atherosclerotic CVD.
    - Coronary artery disease (angina, MI, CABG, PCI).
    - Cerebrovascular disease (stroke, TIA).
    - Peripheral arterial disease.
    - Heart failure.
    - Abdominal aortic aneurysm.
    - Renal failure: serum creatinine >3 mg/dl (GFR <15 or on dialysis).
3. TREATMENT

a) LIFESTYLE MODIFICATION

ADVICE IN ALL PATIENTS

- Reduce weight if overweight by 5 kg over 4-6 month or achieve healthy body weight.
- Regular physical exercise of brisk walking (30-60 minutes) at least 5 days per week.
- Reduce salt intake to less than 5 g of sodium chloride/day. Salt restriction is essential particularly in elderly, diabetics and CKD. List of food items rich in salt should be available in doctors' offices.
- Encourage intake of healthy diet rich in fresh fruits, vegetables, and low-fat dairy products with a reduced content of saturated and total fat.
- Stop smoking.
- Control stress with regular physical activity, behavior modification, change home and work environment conditions, if possible.
## Dietary Approaches to Stop Hypertension (DASH) diet

<table>
<thead>
<tr>
<th>Food group</th>
<th>Servings</th>
<th>Examples and notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grains</td>
<td>7–8/day</td>
<td>Whole wheat bread, oatmeal, popcorn</td>
</tr>
<tr>
<td>Vegetables</td>
<td>4–5/day</td>
<td>Tomatoes, potatoes, carrots, beans, peas, squash, spinach</td>
</tr>
<tr>
<td>Fruits</td>
<td>4–5/day</td>
<td>Apricots, bananas, grapes, oranges, grapefruit, melons</td>
</tr>
<tr>
<td>Low-fat or fat-free dairy foods</td>
<td>2–3/day</td>
<td>Fat-free (skimmed) or low-fat (1%) milk, fat-free or low-fat yogurt, fat-free or low-fat cheese</td>
</tr>
<tr>
<td>Meats, poultry, fish</td>
<td>≤2/day</td>
<td>Select only lean meats. Trim away fats. Broil, roast or boil. No frying. Remove skin from poultry</td>
</tr>
<tr>
<td>Nuts, seeds, dry beans</td>
<td>4–5/week</td>
<td>Almonds, peanuts, walnuts, sunflower seeds, soybeans, lentils</td>
</tr>
<tr>
<td>Fats and oils</td>
<td>2–3/day</td>
<td>Soft margarines, low-fat mayonnaise, vegetable oil (olive, corn, canola or safflower)</td>
</tr>
<tr>
<td>Sweets</td>
<td>5/week</td>
<td>Maple syrup, sugar, jelly, jam, hard candy, sorbet</td>
</tr>
</tbody>
</table>


Examples of single servings for each food group are listed below.

**Grains**
- 1 slice whole-wheat bread  
- 1 ounce dry whole-grain cereal  
- 1/2 cup cooked cereal, rice or pasta (preferably whole grain)

**Vegetables**
- 1 cup raw leafy green vegetable  
- 1/2 cup cut-up raw or cooked vegetables  
- 1/2 cup (4 fluid ounces) low-sodium vegetable juice

**Fruits**
- 1 medium fruit  
- 1/4 cup dried fruit  
- 1/2 cup fresh, frozen or canned fruit  
- 1/2 cup (4 fluid ounces) 100% fruit juice

**Milk and milk products**
- 1 cup (8 fluid ounces) low-fat or fat-free milk  
- 1 cup low-fat or fat-free yogurt  
- 1 1/2 ounces low-fat or fat-free cheese

**Meat, poultry and fish**
- 1-ounce cooked lean meat, skinless poultry or fish  
- 1 egg  
- 2 egg whites

**Nuts, seeds and legumes**
- 1/3 cup (1 1/2 ounces) nuts  
- 2 tablespoons peanut butter  
- 2 tablespoons (1/2 ounce) seeds  
- 1/2 cup cooked legumes (dried beans or peas)
Fats and oils
- 1 teaspoon soft margarine
- 1 teaspoon vegetable oil
- 1 tablespoon mayonnaise
- 2 tablespoons low-fat salad dressing (or 1 tablespoon regular dressing)

Sweets and added sugars
- 1 tablespoon sugar
- 1 tablespoon jelly or jam
- 1/2 cup sorbet
- 1 cup (8 fluid ounces) sugar-sweetened lemonade

<table>
<thead>
<tr>
<th>Food Items to Be Avoided in Hypertensive Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Table salt (sodium chloride)</td>
</tr>
<tr>
<td>- Baking powder</td>
</tr>
<tr>
<td>- Sodium bicarbonate</td>
</tr>
<tr>
<td>- Fried food</td>
</tr>
<tr>
<td>- Salt preserved foods</td>
</tr>
<tr>
<td>- Pickles and canned foods</td>
</tr>
<tr>
<td>- Ketchup and sauces</td>
</tr>
<tr>
<td>- Ready to eat foods (fast foods)</td>
</tr>
<tr>
<td>- Highly salted foods</td>
</tr>
<tr>
<td>- Potato chips, cheese, peanut butter</td>
</tr>
<tr>
<td>- Salted butter, salted nuts, salted fish</td>
</tr>
<tr>
<td>- Bakery products</td>
</tr>
<tr>
<td>- Biscuits, cakes, salted breads</td>
</tr>
</tbody>
</table>
Antihypertensive drugs can be classified into 3 big categories:

1. First line or drugs of first choice which include thiazides and thiazide-like diuretics (D), beta adrenergic blockers (BB), calcium channel blockers (CCB), angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). There is an evidence from clinical trials that drugs in this group can improve prognosis and prevent TOD and disease progression.

2. Second line or accessory drugs which include: loop and potassium sparing diuretics, central sympathectics (methyldopa and clonidine), peripheral sympathetics, (reserpine, guanethidine), α1 adrenergic blockers (prazosin and doxazosin) and direct arterial vasodilators (hydralazine and minoxidil).

3. Drug combinations: combining 2 drugs from different pharmacologic groups in a single pill.

Initiation of drug therapy depends upon the patient global cardiovascular risk profile, level of BP and its response to lifestyle modification.

Drug therapy should be started immediately in case of hypertensive emergencies and urgencies, otherwise a trial of non-pharmacologic treatment (lifestyle modification) for a period of weeks to months is recommended while monitoring BP on frequent office visits or at home before initiating drug treatment.

The selection of the drug for initial treatment depends upon the presence of any compelling indications for a specific pharmacologic group such as coronary disease, heart failure, diabetes or chronic kidney disease (CKD).

In patients with more than mild hypertension (≥160/100 mmHg) and high risk patients, it is recommended to initiate therapy with a combination of two drugs.

The BP target will vary from <150/95 mmHg in elderly patients to <130/80 mmHg in high risk patients.

In patients with mild hypertension with low risk profile, drug therapy may not be needed. Lifestyle modification and regular BP monitoring is the recommended policy.
When to Initiate Drug Therapy?
Blood pressure threshold and duration of initial monitoring

<table>
<thead>
<tr>
<th>Population</th>
<th>LSM Duration</th>
<th>SBP</th>
<th>DBP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low risk patients</td>
<td>3-6 m</td>
<td>160</td>
<td>100</td>
</tr>
<tr>
<td>Moderate and high risk (≥ 2 RFs, DM, TOD, CKD)</td>
<td>3-6 w</td>
<td>140</td>
<td>90</td>
</tr>
<tr>
<td>Very high risk patients*</td>
<td>1-2 w</td>
<td>130</td>
<td>80</td>
</tr>
<tr>
<td>Elderly</td>
<td>3-6 w</td>
<td>150</td>
<td>90</td>
</tr>
</tbody>
</table>

* Associated CV disease: CAD, cerebrovascular, HF, peripheral arterial disease and aortic aneurysm. CKD with proteinuria > 500 mg/24 hrs
  • m: month, w: week, LSM: lifestyle modification

TIMING OF INITIATION OF DRUG THERAPY

1. Immediate: on the first office or hospital visit
   a. Hypertensive emergency.
   b. BP >210/120 mmHg on 3 consecutive measurements, 2-3 minutes apart after excluding a panic attack.
   c. BP >180/110 mmHg on 3 consecutive measurements (2-3 minutes apart) in the presence of:
      ▪ TOD: LVH (ECG, clinical, echo), proteinuria, elevated serum creatinine (>1.5 mg/dl in males, >1.4 mg/dl in females), optic fundus > grade I retinopathy, aortic aneurysm, carotid bruits.
      ▪ Symptomatic CVD (CAD, HF), stroke, transient ischemic attack (TIA), peripheral arterial disease (PAD), chronic kidney disease (CKD).

2. Within days to months after 1st office visit

<table>
<thead>
<tr>
<th>Timing of Initiation (office visits)</th>
<th>BP Grade</th>
<th>Risk Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-3 weeks (2 visits)</td>
<td>Severe</td>
<td>Moderate</td>
</tr>
<tr>
<td></td>
<td>Moderate</td>
<td>High</td>
</tr>
<tr>
<td></td>
<td>Mild</td>
<td>Very high</td>
</tr>
<tr>
<td>1-3 m (2-4 visits)</td>
<td>Moderate</td>
<td>Moderate</td>
</tr>
<tr>
<td></td>
<td>Mild</td>
<td>High</td>
</tr>
<tr>
<td>3-6 m (2-3 visits)</td>
<td>Mild</td>
<td>Moderate</td>
</tr>
<tr>
<td>&gt;6 m (2-3 visits)</td>
<td>Mild</td>
<td>Low</td>
</tr>
</tbody>
</table>

BP grades: mild (140-159/90-99), moderate (160-179/100-109), severe (≥ 180/110 mmHg)
### Selection of Antihypertensive Drugs

<table>
<thead>
<tr>
<th>Class of Drug</th>
<th>Indications</th>
<th>Contraindications</th>
<th>Caution or Limited Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Thiazide and Thiazide-Like Diuretics</strong></td>
<td>- Heart failure&lt;br&gt;- Elderly patients&lt;br&gt;- Black patients&lt;br&gt;- Obese patients&lt;br&gt;- Other low renin forms: diabetes, CKD</td>
<td>Gout</td>
<td>- Pregnancy&lt;br&gt;- Hypokalemia&lt;br&gt;- Advanced RF</td>
</tr>
<tr>
<td><strong>Beta-Blockers</strong></td>
<td>- CAD&lt;br&gt;- Tachyarrhythmias&lt;br&gt;- Pregnancy&lt;br&gt;- Increased adrenergic activity&lt;br&gt;- Heart failure, hypertrophic cardiomyopathy&lt;br&gt;- Associated: migraine, anxiety, tremors, hyperthyroidism</td>
<td>- Heart block (&gt;grade I)&lt;br&gt;- Bronchial asthma requiring inhalation therapy&lt;br&gt;- Symptomatic bradycardia (&lt;50 beats/m)</td>
<td>- Blacks&lt;br&gt;- Elderly</td>
</tr>
<tr>
<td><strong>ACE inhibitors/ ARBs</strong></td>
<td>- Heart failure&lt;br&gt;- After MI&lt;br&gt;- Diabetes&lt;br&gt;- Microalbuminuria&lt;br&gt;- Proteinuric CKD&lt;br&gt;- Target organ damage (LVH, CV disease, PAD)</td>
<td>- Pregnancy&lt;br&gt;- Bilateral renal artery stenosis&lt;br&gt;- Sensitivity (angioneurotic edema)</td>
<td>- S. creatinine elevation&lt;br&gt;- Blacks&lt;br&gt;- Hyperkalemia&lt;br&gt;- Acute renal failure</td>
</tr>
<tr>
<td><strong>CCB</strong></td>
<td>- Angina&lt;br&gt;- Peripheral vascular disease&lt;br&gt;- Elderly patients&lt;br&gt;- Systolic hypertension&lt;br&gt;- Black patients&lt;br&gt;- Excessive BP fluctuations</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>α1 Blockers: Prazosin (combined with diuretics)</strong></td>
<td>- Benign (senile) prostatic hypertrophy&lt;br&gt;- Dyslipidemia</td>
<td></td>
<td>- Postural hypotension</td>
</tr>
</tbody>
</table>

### Blood Pressure Targets
- < 140/90 mmHg in low risk patients
- < 140/90 mmHg: ≥ 2 risk factors, diabetes, CKD, TOD
- < 130/80 mmHg: HF, CKD or diabetes when associated with proteinuria >1 gm/24 hrs.
- < 150/90 mmHg in the elderly (≥65 years).
SELECTING FIRST-LINE THERAPY

In absence of compelling indications for a specific pharmacologic group:

- In mild-moderate hypertension without TOD or symptomatic CVD, initiate monotherapy from any of the 5 standard pharmacologic groups (diuretics, BB, CCB, ACEIs, ARBs) preferably a Thiazide diuretic. In elderly (age >65 years) or in blacks, it is preferable to start with diuretic or CCB. In young, particularly those with tachycardia start with BB.
- In moderate or high-risk patients or those with BP ≥160/100 mmHg, start with combination therapy.
- ACEIs or ARBs are not recommended as monotherapy in black patients in absence of compelling indications.
- Aim at gradual BP reduction particularly in the elderly to achieve target BP in 2 months. In high-risk patients and in the presence of severe hypertension, aim to achieve target BP at 2-4 weeks through combination therapy.

Recommended Drug Selection in Absence of Compelling Indications

Escalating and modifying treatment at 4-week intervals according to BP response and patient's tolerance.

**Step I:** Any of the following groups;

1. HCT ± amiloride or chlorothalidone or HCT + spironolactone in the smallest dose e.g. half tablet (HCT 12.5 mg) or indapamide in all patients particularly elderly, blacks and obese.
2. BB: cardio-selective with long activity e.g. bisoprolol 2.5-5.0 mg specially in the young (<65), females or those with rapid and hyperdynamic heart.
3. Amlodipine: 2.5-5.0 mg specially in elderly patients.
4. ACEIs or ARBs.
5. Combine 1 + 2 or 1 + 3 or 2 + 3 or 1+4 if BP > 160/100 mmHg (A single pill combination is recommended).

**Step II:** Combine diuretic in step (1) + two other groups if inadequate response.

**Step III:** Increase dose of amlodipine to 10 mg, if used.

**Step IV:** Increase dose of ACEI or ARB, if used.

**Step V:** Use the four drug groups.

**Step VI:** Add loop diuretic preferably long acting e.g. torsemide (5-20 mg).

**Step VII:** Add spironolactone (12.5-25 mg).
Algorithm (2): First line treatment of adults with systolic/diastolic hypertension without other compelling indications

TARGET <140 mmHg systolic and <90 mmHg diastolic

INITIAL TREATMENT

Lifestyle Modification

- Thiazide/thiazide-like
- ACEI
- ARB
- Long-acting CCB
- Beta-Blocker
- Single pill combination (SPC)

* Longer-acting (thiazide-like) diuretics are preferred over shorter-acting (thiazide) diuretics
† BBs are not indicated as first line therapy for age 50 and above
‡ Renin angiotensin system (RAS) inhibitors are contraindicated in pregnancy and caution is required in prescribing to women of child-bearing potential

**Recommended SPC choices are those in which an ACE-I is combined with a CCB, an ARB with a CCB, or an ACE-I or ARB with a diuretic
Algorithm (3): Monitoring of Drug Therapy

What to Do If there is Inadequate BP Response?
   a. Ensure salt reduction, LSM & Stress control.
   b. Add thiazide if not given initially.
   c. Add another agent (different pharmacologic group).
   d. Substitute with another agent if the above measures fail.
   e. Seek specialist’s opinion.

Frequency of Checking BP (Interval to Next Visit)

Low/intermediate risk
- 1-2 m interval
  - Absent response
    - BP not at target
      - Add another drug
      - Recheck in 1-2 m
  - BP at target on 2 consecutive visits
    - Recheck in 3-6 m

High Risk
- 2 W interval
  - BP at target on 2 consecutive visits
  - Not at target
    - Add a 3rd drug
    - Recheck in 1 m
  - Recheck in 1 m
c) **MEASURES TO IMPROVE PATIENT’S COMPLIANCE**

1. **Patient education:**
   - Physician should spend few minutes with his/her patient during office visit to discuss the following facts:
     a. Hypertension is silent; one can not rely on symptoms to diagnose high blood pressure.
     b. Treatment of hypertension is lifelong and without interruption.
     c. Hypertension is not treated on demand i.e. to give drugs when blood pressure is elevated and stop it when blood pressure is normal.
     d. Hypertension requires life-long monitoring. Blood pressure should be measured regularly at 3 to 6 months intervals, depending on risk profile and level of blood pressure.
     e. Lifestyle modification is an important component of the therapeutic regimen.
     f. Antihypertensive drugs can produce side effects.

2. **Prescribe affordable drugs.**

3. **Regular follow-up (3-6 months).**

4. **Keep inexpensive and simple care:**
   a. Do the least needed work-up.
   b. Add one drug at a time and use the least number of pills.
   c. Start with a small dose.

5. **Encourage patient to check his blood pressure at home** provided that he has a reliable well-maintained device and he is well trained to measure blood pressure accurately. Home blood pressure measurement will improve compliance but not recommended if it causes anxiety and patient should be advised not to change his blood pressure medicines without the consultation of his physician.
**Hypertension Associated with Cardiovascular Disease**

- In chronic stable angina, target BP is <140/90 mmHg. B-blockers, calcium channel blockers and ACE-inhibitors are 1st line drugs. Excessive lowering of diastolic BP (<70 mmHg) should be avoided.
- In acute coronary syndromes associated with hypertension, B-blockers, non-dihydropyridine CCB, and IV nitrate are recommended.
- In systolic HF, target BP is <130/80 mmHg. ACE-inhibitors (or ARB), B-blockers, and diuretics including aldosterone antagonists are the recommended agents. Other agents include amlodipine, felodipine, and hydralazine.
- Patients with evidence of left ventricular hypertrophy should receive an ACE inhibitor or ARB, complemented if necessary, with a CCB.
- Treatment of hypertension with significant aortic stenosis should be done cautiously.
- Hypertension is a risk factor for atrial fibrillation, and it is also a major risk factor for AF-related thromboembolism. Uncontrolled hypertension increases the bleeding risk in patients receiving anticoagulant therapy.

**Hypertension Associated with Renal Diseases**

- Measurements of proteinuria at 6-12 months
- Aim at reduction of micro-albuminuria by >30% within 6 months of starting treatment
- Salt restriction to 2-3 g/d will reduce urinary protein excretion
- Need to lower BP in patients with >1 g protein excretion/d (<130/80 mmHg) and use RAS blockade.
- In absence of albuminuria, BP target is <140/90 mmHg
- Choice of diuretic should be guided by GFR, if <50 ml/min, use a loop diuretic.
Causes of Exaggerated or Progressive Decline in Renal Function Associated with ACE-inhibitors or Angiotensin Receptor Blockers Use

- Bilateral renal artery stenosis.
- Renal artery stenosis in a single functioning kidney.
- Polycystic kidney disease.
- Absolute reduction in intravascular volume (gastroenteritis, aggressive diuresis)
- Reduction in effective arterial volume (moderate to severe CHF).
- Use of NSAIDs or calcineurin inhibitors (increased renal vasoconstriction).

DIABETES AND HYPERTENSION

Diabetic Hypertensives

- Increased sensitivity to dietary sodium.
- Loss of nocturnal decline in blood pressure.
- Tendency to orthostatic hypotension.
- Recommend diet: low fat, low Na, high fiber, low calories.
- RAS blockade is the cornerstone of therapy.
- Diuretics are required for good BP control e.g. low dose HCT (12.5-25 mg).
- In the presence of proteinuria (1 gm/24 h), blood pressure target <130/80 mmHg.

OBSTRUCTIVE SLEEP APNEA (OSA)

- OSA is considered one of the potentially reversible secondary causes of hypertension and among the causes of resistant hypertension.
- OSA is characterized by recurrent episodes of cessation of respiratory airflow caused by upper airway inspiratory collapse during sleep, with a consequent decrease in oxygen saturation.
- Hypertension affects approximately 50% of patients with OSA.
- In addition to weight control and continues positive airway pressure, spironolactone may be particularly effective in controlling blood pressure because of secondary hyperaldosteronism in patients with OSA.
**Resistant Hypertension**

- Resistant hypertension is defined as persistent elevation of blood pressure above the target in patients who are adhering to triple-drug regimen including a diuretic, and all three drugs are prescribed in maximum recommended and tolerated doses for at least three months.
- For older patients with isolated systolic hypertension, resistance is defined as failure of an adequate triple-drug regimen to reduce systolic blood pressure below 160 mmHg.
- The diagnosis of resistant hypertension requires accurate blood pressure measurement to confirm persistently elevated blood pressure levels.
- Referral to a specialist should be considered.
- Although an inadequate response to antihypertensive therapy is unfortunately common, true resistant hypertension is not common in general practice.
- Factors contributing to resistant hypertension include white coat hypertension, inadequate therapy, lack of patient's compliance, failure of correction of obesity, sleep apnea, intake of pressor drugs and excess salt intake. If loop diuretics and spironolactone in addition to adequate dose of triple pharmacologic therapy fail, consider secondary forms. ABPM and detailed laboratory evaluation is needed in this group.

**Substances that Can Elevate Blood pressure**

<table>
<thead>
<tr>
<th>NSAIDs (nonsteroidal anti inflammatory drugs).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral contraceptives.</td>
</tr>
<tr>
<td>Glucocorticoids.</td>
</tr>
<tr>
<td>Mineralocorticoids.</td>
</tr>
<tr>
<td>Sympathomimetics (e.g., nasal decongestants, appetite suppressants).</td>
</tr>
<tr>
<td>Licorice.</td>
</tr>
<tr>
<td>Phenothiazines.</td>
</tr>
<tr>
<td>Antidepressants.</td>
</tr>
<tr>
<td>Cyclosporine.</td>
</tr>
<tr>
<td>MAO inhibitors and tyramine rich foods.</td>
</tr>
<tr>
<td>Erythropoietin.</td>
</tr>
<tr>
<td>Cocaine.</td>
</tr>
</tbody>
</table>
Hypertension in the Elderly

- Hypertension in the elderly is characterized by excess BP variability, postural changes, white coat effect, sensitivity to salt intake and associated co-morbidities. Diuretics and CCB are the drugs of first choice.
- BP goal in the elderly is <150/90 mmHg.
- Reduction in cardiovascular morbidity and mortality can be achieved with antihypertensive treatment even above 80 years.
- The diagnostic pitfalls of pseudo-hypertension, auscultatory gap and white coat hypertension should be carefully considered in these patients.
- Because of the increased risk of postural hypotension in the elderly, BP should always be measured also in standing posture.

Source: M. Mohsen Ibrahim, 2013
Management of Elderly Hypertensive

- Start with smaller antihypertensive doses, at almost half the standard doses and increase the dose gradually over several weeks.
- Check for adverse drug reactions which are two to three times more common in the elderly.
- Follow-up visits should be scheduled every two to four weeks until blood pressure is controlled.

Hypertensive Emergencies

- Hypertensive crisis is arbitrarily defined as severe elevation of blood pressure (exceeding 220 mmHg systolic and/or 120 mmHg diastolic). It is considered an emergency when complicated by acute progressive target organ damage such as encephalopathy, cerebral hemorrhage, pulmonary edema, aortic dissection etc…….
- Patients who present with severe elevation of blood pressure in the absence of acute target organ damage have hypertensive urgency. They can be managed as out-patients using a combination of rapidly acting oral antihypertensive drugs such as calcium channel blockers or sympatholytic. Sublingual administration should NOT be used.
- Patients who present with a hypertensive emergency should be hospitalized for rapid controlled lowering of blood pressure in the ICU. The target blood pressure level and the rate of reduction depend on the nature of emergency, the age of the patient and the clinical response.
- The antihypertensive drugs of choice (sodium nitroprusside, nitroglycerin) are rapidly acting parenteral agents with a short duration of action which effectively reduce the systemic vascular resistance. Their action can be rapidly reversed in case of excessive hypotension.
General Principles

- Avoid using rapidly acting **sublingual** nifedipine and captopril that may result in uncontrolled reduction of arterial pressure and marked organ hypoperfusion leading to catastrophic end-organ damage such as cerebral infarction, or acute myocardial infarction
- **Intravenous** diuretics should not be used as initial therapy in a hypertensive crisis unless the patient presents in acute pulmonary oedema or there is evidence of extracellular volume expansion
- Avoid rapid and uncontrolled reduction in blood pressure to the normal level within the first few hours, that may lead to target organs hypoperfusion. The mean arterial pressure should be reduced to a level of 120 mmHg (160/100) over several hours. In patients with acute pulmonary edema or aortic dissection, rapid lowering of BP (within <1 hour) may be needed.

Types and Clinical Presentation of Hypertensive Emergencies

<table>
<thead>
<tr>
<th>Type</th>
<th>Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Malignant hypertension with papilloedema</strong></td>
<td></td>
</tr>
</tbody>
</table>
| **Cerebrovascular** | - Hypertensive encephalopathy  
- Atherothrombotic brain infarction with severe hypertension  
- Intracerebral haemorrhage  
- Subarachnoid haemorrhage |
| **Cardiac** | - Acute aortic dissection  
- Acute left ventricular failure  
- Acute myocardial infarction |
| **Renal** | - Acute glomerulonephritis  
- Renal crisis from collagen vascular disease  
- Severe hypertension after kidney transplantation |
| **Excessive circulating catecholamines** | - Pheochromocytoma crisis  
- Food or drug interactions with monoamine-oxidase inhibitors  
- Sympathomimetic drug use (cocaine)  
- Rebound hypertension after sudden cessation of antihypertensive drugs e.g. clonidine. |
| **Eclampsia** | |
| **Surgical** | - Severe hypertension in patients requiring immediate surgery  
- Postoperative hypertension  
- Postoperative bleeding from vascular suture lines  
- Severe body burns |
Management of Hypertensive Emergencies

Goals of Therapy

- Rapid controlled blood pressure lowering is recommended in cerebral infarction if blood pressure is 220/120 mmHg or greater (180/105 mmHg in patients with cerebral hemorrhage). Do not lower mean blood pressure by more than 25% in the first two hours, then to 160/100 mmHg within the next six hours.
- Rapid reduction of blood pressure to normal levels is indicated in patients with aortic dissection, acute pulmonary oedema, and cerebral hemorrhage.
- The primary goal of the emergency physician is to determine which patients with acute hypertension are exhibiting symptoms of end-organ damage and require immediate intravenous (IV) parenteral therapy. In contrast, patients presenting with acutely elevated BP (systolic BP [SBP] >200 mm Hg or diastolic BP [DBP] >120 mm Hg) without symptoms and whose BP stays significantly elevated to this level on discharge should have initiation of medical therapy and close follow-up in the outpatient setting.

Hypertension in Women

- The use of estrogen-containing oral contraceptive (OC) pills can cause secondary hypertension in young women.
- Newer progestins such as drospirenone contain a spironolactone-like moiety with mild mineralocorticoid antagonist action; as a result, drospirenone-estrogen combinations generally cause a small decrease in BP.
- Mild preeclampsia is managed by close observation of the mother and fetus preferably in hospital. If the diastolic blood pressure remains persistently >100 mmHg, oral antihypertensive drug therapy is instituted.
- The oral antihypertensive drug of choice in pregnancy is methyldopa. Alternatives include CCB blockers and labetalol.

Hypertension in Children and Adolescents

- The prevalence of hypertension in children and adolescents varies from 1-2%.
- The blood pressure measurement in a child should be compared with the childhood reference data tables based on age, gender and height.
- High blood pressure (hypertension) in children is diagnosed when average systolic blood pressure or diastolic blood pressure (or both) is equal to or greater than the 95th percentile for age and gender.
- Younger children with severe blood pressure elevation may have secondary hypertension, and need careful and laboratory evaluation. The major causes of secondary hypertension in children and adolescents are of renal parenchymal origin.
SECONDARY HYPERTENSION

Patients with any of the following clinical clues, should suggest a secondary cause for hypertension:

- Onset of hypertension before age 25 or after age 60 years.
- Sudden onset change from normal blood pressure to severe hypertension in less than a year.
- Resistant hypertension.
- Poor response to prior effective drug therapy.
- Paroxysmal attacks of hypertension with palpitation, pallor, sweating and tremors.
- Multiple system involvement on initial evaluation.
- Delayed and weak femoral pulses with lower blood pressure in the lower extremities.
- Continuous abdominal bruit.
- Renal masses.
- Advanced end organ damage: more than grade 2 retinopathy or serum creatinine >2.0 mg/dl.
- Laboratory abnormalities: (e.g., hypokalemia, or hypercalcemia).

Causes Of Secondary Hypertension

Renal Causes:
- Chronic renal parenchymal disease (3-5%).
- Renal artery stenosis (1-2%).

Drugs

Endocrinal Causes
- Primary hyperaldosteronism. (5-12%)
- Hyper- or hypothyroidism.
- Pheochromocytoma (<0.3%).
- Cushing syndrome.

Aortic Coarctation.

Other Causes
- Central nervous system diseases e.g., brain tumor.
- Sleep apnea, acute porphyria, polycythemia vera.
Acknowledgement

The EHS Guidelines Working Group appreciates very much the excellent secretarial work of Mrs. Rehab El-Ashkar, who helped in the typing and preparation of the document and for running the logistics of working group meetings.
The Egyptian Ministry of Health & Population endorsed these guidelines as the National Egyptian Guidelines for Egyptian physicians.
Hikma sponsored the printing of this latest guidelines update.
ESC acknowledgement the typing this version work of Mrs. Nesma El-Ashkar.